Courier Health featured prominently this week as it deepened its role in biopharma patient support and AI readiness. The company released its 2026 State of Patient-Centricity in Biopharma report, based on responses from more than 170 senior commercial leaders across 87 firms, highlighting widespread data fragmentation and limited AI maturity.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Nearly 60% of respondents reported fragmented or non-operationalized data, while only 9% said they had the data maturity required for meaningful AI use cases. Governance is lagging as well, with just 12% of companies having approved AI tools and formal oversight, even as larger manufacturers step up automation and AI investments.
The report underscored a structural shift in commercial models, with internal or hybrid Patient Services teams rising from 60% to 75% and Field Access and Reimbursement teams reaching 83% majority internal. These trends expand the base of in-house stakeholders that could benefit from Courier Health’s platform to manage patient journeys and operational performance.
Courier Health also announced a $50 million Series B round led by Oak HC/FT, with participation from existing investors Norwest and Work-Bench. The New York-based company plans to use the funding to advance product innovation, scale its agentic AI capabilities, and grow its team to meet increasing demand from life sciences customers.
The company’s software integrates fragmented patient data and disparate support systems to provide end-to-end visibility from education and enrollment through therapy initiation and adherence. Its context-aware AI surfaces insights, flags at-risk patients, and automates routine tasks to standardize interactions across providers, pharmacies, and patient services teams.
Courier Health reported rapid growth in 2025, boosting the number of customers and supported therapies on its platform by more than 400% and more than doubling headcount. Management expects the new capital and insights from its industry report to help target accounts with acute data and governance gaps while positioning its platform as core infrastructure for data-driven, patient-centric programs.
Taken together, the financing and research publication reinforce Courier Health’s position at the intersection of AI, data infrastructure, and patient services in biopharma. The week’s developments suggest a solid foundation for continued expansion as manufacturers seek structured, compliant solutions to translate AI ambitions into measurable patient and financial outcomes.